



# LUND UNIVERSITY

## **Streptococcal M1 protein triggers farnesyltransferase-dependent formation of CXC chemokines in alveolar macrophages and neutrophil infiltration in the lung.**

Zhang, Songen; Rahman, Milladur; Zhang, Su; Jeppsson, Bengt; Herwald, Heiko; Thorlacius, Henrik

*Published in:*  
Infection and Immunity

*DOI:*  
[10.1128/IAI.00696-12](https://doi.org/10.1128/IAI.00696-12)

2012

[Link to publication](#)

### *Citation for published version (APA):*

Zhang, S., Rahman, M., Zhang, S., Jeppsson, B., Herwald, H., & Thorlacius, H. (2012). Streptococcal M1 protein triggers farnesyltransferase-dependent formation of CXC chemokines in alveolar macrophages and neutrophil infiltration in the lung. *Infection and Immunity*, 80(11), 3952-3959. <https://doi.org/10.1128/IAI.00696-12>

*Total number of authors:*  
6

### **General rights**

Unless other specific re-use rights are stated the following general rights apply:  
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00

Streptococcal M1 protein triggers farnesyltransferase-dependent formation of CXC chemokines in  
alveolar macrophages and neutrophil infiltration in the lung

Running title: Farnesyltransferase and streptococcal M1 protein

Songen Zhang<sup>1</sup>, Milladur Rahman<sup>1</sup>, Su Zhang<sup>1</sup>, Bengt Jeppsson<sup>1</sup>, Heiko Herwald<sup>2</sup> and  
Henrik Thorlacius<sup>1,#</sup>

<sup>1</sup>Department of Clinical Sciences, Section for Surgery, 20502 Malmö and <sup>2</sup>Department of Clinical  
Sciences, Lund, Division of Infection Medicine 22184 Lund, Lund University, Sweden

---

# Correspondence and Request for Reprints to:

Henrik Thorlacius, MD, PhD  
Department of Surgery  
Malmö University Hospital  
Lund University  
205 02 Malmö, SWEDEN  
Telephone: Int+46-40-331000  
Telefax: Int+46-40-336207  
E-mail: [henrik.thorlacius@med.lu.se](mailto:henrik.thorlacius@med.lu.se)

## ABSTRACT

M1 serotype of *Streptococcus pyogenes* plays an important role in streptococcal toxic shock syndrome. Simvastatin, a HMG-CoA reductase inhibitor, has been shown to inhibit streptococcal M1 protein-induced acute lung damage although downstream mechanisms remain elusive. Protein isoprenylation, such as farnesylation and geranylgeranylation, has been suggested to regulate anti-inflammatory effects exerted by statins. Herein, we examined the effect of a farnesyltransferase inhibitor (FTI-277) on M1 protein-triggered lung inflammation. Male C57BL/6 mice were treated with FTI-277 prior to M1 protein challenge. Bronchoalveolar fluid and lung tissue were harvested for quantification of neutrophil recruitment, edema and CXC chemokine formation. Flow cytometry was used to determine Mac-1 expression on neutrophils. Gene expression of CXC chemokines was determined in alveolar macrophages by using quantitative RT-PCR. We found that administration of FTI-277 markedly decreased M1 protein-induced accumulation of neutrophils, edema formation and tissue damage in the lung. Notably, inhibition of farnesyltransferase abolished M1 protein-evoked production of CXC chemokines in the lung and gene expression of CXC chemokines in alveolar macrophages. Moreover, FTI-277 completely inhibited chemokine-induced neutrophil migration *in vitro*. However, farnesyltransferase inhibition had no effect on M1 protein-induced expression of Mac-1 on neutrophils. Our findings suggest that farnesyltransferase is a potent regulator of CXC chemokine formation in alveolar macrophages and that inhibition of farnesyltransferase not only reduces neutrophil recruitment but also attenuates acute lung injury provoked by streptococcal M1 protein. We conclude that farnesyltransferase activity is a potential target in order to attenuate acute lung damage in streptococcal infections.

Key words: Farnesyltransferase, Chemokines, Neutrophils, Streptococcal infection

## INTRODUCTION

Streptococcal toxic shock syndrome (STSS) is a fatal condition associated with acute lung injury (2, 5, 24). Due to the limited understanding of the underlying pathophysiology, management of patients with STSS poses a major challenge to clinicians, and is largely limited to antibiotics and supportive therapy. It is known that the M1 serotype of *Streptococcus pyogenes* is most frequently associated with fatal STSS (14, 25). M1 protein is a potent stimulator of neutrophils (40) and STSS-associated lung injury is characterized by massive infiltration of neutrophils (321, 39). Neutrophils are generally considered to be the first line of defence against microbial invasion. Nonetheless, overwhelming neutrophil infiltration appears to constitute a rate-limiting step in the pathophysiology M1 protein-induced lung damage. For example, systemic depletion of neutrophils abolishes acute lung injury in mice challenged with M1 protein (32, 40). Chemokines are known to be key regulators of leukocyte trafficking at sites of inflammation. CXC chemokines, such as CXCL1 and CXCL2, orchestrate tissue recruitment of neutrophils. CXCR2 (IL-8 receptor B) is the high affinity receptor on murine neutrophils for CXCL1 and CXCL2 (16). Herbold et al. (2010) have shown that CXCR2 is critical in mediating pulmonary recruitment of neutrophils in streptococcal infection (13). Moreover, a recent study reported that M1 protein-provoked accumulation of neutrophils in the lung is mediated by CXCR2 (39). Although the role of CXC chemokines appears convincing the intracellular signaling mechanisms controlling CXC chemokine formation in M1 protein-induced lung injury are not known.

Statins are mainly used to control cholesterol levels in patients with cardiovascular diseases. However, recent studies have suggested that statins might reduce morbidity and mortality in septic patients (17, 29). Moreover, several reports indicate that statin treatment inhibits

pulmonary damage (39) and increases survival in murine sepsis (21, 22). Indeed, we have recently shown that simvastatin is a potent inhibitor of M1 protein-triggered neutrophil recruitment and lung damage (40). Convincing data in the literature demonstrate that statins, such as simvastatin, exert pleiotropic anti-inflammatory effects, including attenuated expression of cytokines, chemokines, and adhesion molecules as well as decreased formation of nitric oxide (10, 34, 36). Statins inhibit HMG-CoA reductase, which is the rate-limiting enzyme in mevalonate formation (3). Mevalonate is a precursor of farnesyl pyrophosphate and geranylgeranyl pyrophosphate, which are critical in protein isoprenylation, such as farnesylation and geranylgeranylation. Farnesyltransferase catalyzes attachment of farnesyl pyrophosphate to cysteine residues in small regulatory proteins, such as small G proteins of the Ras-homologous (Rho) family needed for a broad range of cellular functions, including membrane trafficking, cytoskeletal organization, growth, apoptosis, and differentiation (18, 27). Interestingly, a recent study reported that inhibition of farnesyltransferase antagonized T-lymphocyte infiltration in the nervous system (35). However, the potential role of farnesyltransferase in regulating pulmonary recruitment and tissue damage in M1 protein-induced inflammation remains elusive.

Based on the above considerations, we hypothesized that farnesyltransferase activity might be involved in streptococcal M1 protein-induced neutrophil infiltration and tissue damage in the lung.

## MATERIALS AND METHODS

### *Animals*

Male C57BL/6 mice weighing 20 to 25 g were used for experiments and kept under standard laboratory conditions, maintained on a 12-12 h light dark cycle and fed a laboratory diet and water ad libitum. Animals were anesthetized with 75 mg of ketamine hydrochloride (Hoffman-La Roche, Basel, Switzerland) and 25 mg of xylazine (Janssen Pharmaceutica, Beerse, Belgium) per kg body weight. All experimental procedures were performed in accordance with the legislation on the protection of animals and were approved by the Regional Ethical Committee for Animal Experimentation at Lund University, Sweden.

### *Experimental model*

M1 protein was purified from the isogenic mutant MC25 strain (derived from the AP1 *Streptococcus pyogenes* strain 40/58 from the WHO Collaborating Centre for references and Research on Streptococci, Institute of Hygiene and Epidemiology, Prague, Czech Republic) as described previously (4). Mice were intravenously injected with 15 µg of M1 protein in phosphate-buffered saline (PBS). M1 protein was purified from a mutated *Streptococcus pyogenes* strain making the likelihood of endotoxin contamination close to zero. Nevertheless we also measured the endotoxin content in the M1 protein samples and confirmed that endotoxin levels were below the detection limit. Sham mice received PBS intravenously (i.v.) only. The farnesyltransferase inhibitor, FTI-277 (2.5 or 25 mg/kg, Sigma Chemical Co., St. Louis, MO, USA) or vehicle (PBS) was administered intraperitoneally (i.p.) 10 min prior to M1 protein challenge. FTI-277 was dissolved in sterile distilled water and diluted by PBS just before injection. Animals were re-anesthetized 4 h after M1 protein challenge. The left lung was ligated

and excised for edema measurement. The right lung was used for collecting bronchoalveolar lavage fluid (BALF) to quantify neutrophils. Then, the lung was excised and one lobe was fixed in formaldehyde for histology and the remaining lung tissue was snap-frozen in liquid nitrogen and stored at -80 °C for later myeloperoxidase (MPO) assay and enzyme-linked immunosorbent assay (ELISA) as described subsequently.

#### *Systemic leukocyte count*

Blood was collected from the tail vein and mixed with Turks solution (0.2 mg gentian violet in 1 ml glacial acetic acid, 6.25% v/v) in a 1:20 dilution. Leukocytes were identified as monomorphonuclear (MNL) and polymorphonuclear (PMNL) cells in a Burker chamber.

#### *Lung edema*

The left lung was excised, washed in PBS, gently dried using a blotting paper and weighed. The tissue was then dried at 60°C for 72 h and re-weighed. The change in the ratio of wet weight to dry weight was used as indicator of lung edema formation.

#### *MPO activity*

Lung tissue was thawed and homogenized in one ml of 0.5% hexadecyltrimethylammonium bromide. Samples were freeze-thawed, after which the MPO activity of the supernatant was determined spectrophotometrically as the MPO-catalysed change in absorbance in the redox reaction of H<sub>2</sub>O<sub>2</sub> (450 nm, with a reference filter 540 nm, 25°C) as previously described (1). Values were expressed as MPO units per g tissue.

*BALF*

Animals were placed supine and the trachea was exposed by dissection. A catheter was inserted into the trachea. BALF was collected by 5 washes of 1 ml of PBS containing 5 mM EDTA. The numbers of MNL and PMNL cells were counted in a Burker chamber.

*ELISA*

Levels of CXCL1 and CXCL2 in lung homogenates were analyzed by using double antibody Quantikine ELISA kits (R & D Systems, Europe, Abingdon, Oxon, UK) using recombinant murine CXCL1 and CXCL2 as standards. The lower limit of the assay was 0.5 pg/ml.

*Flow cytometry*

For analysis of surface molecules expression on circulating neutrophils, blood was collected (1:10 acid citrate dextrose) 4 h after M1 protein challenge and incubated (10 min, RT) with an anti-CD16/CD32 antibody blocking Fc  $\gamma$  III/II receptors to reduce non-specific labeling and then incubated with PE-conjugated anti-Gr-1 (clone RB6-8C5, rat IgG2b, eBioscience, San Diego, CA, USA), and FITC-conjugated anti-Mac-1 (clone M1/70, integrin  $\alpha_M$  chain, rat IgG2b). The mean fluorescence intensity (MFI) was determined by comparing to an isotype control antibody (FITC-conjugated rat IgG2b). All antibodies were purchased from BD Biosciences Pharmingen, San Jose, CA, USA except indicated. Cells were fixed and erythrocytes were lysed by BD lysis buffer (BD Biosciences, USA) and then neutrophils were recovered following centrifugation. Flow-cytometric analysis was performed by first gating the neutrophil population of cells based on forward and side scatter characteristics and then Mac-1 expression was determined on Gr-1<sup>+</sup> cells in this gate on a FACSCalibur flow cytometer (Becton Dickinson,



Mountain View, CA, USA). A PE-conjugated anti-mouse F4/80 (clone BM8, Biolegend) was used to identify macrophages isolated from the lung (20, 41). Flow-cytometric analysis was performed by first gating the macrophage population of cells based on forward and side scatter characteristics and then percentage of macrophage in BALF was determined on F4/80<sup>+</sup> cells in this gate on a FACSCalibur flow cytometer.

### *Histology*

Lung samples were fixed in 4% formaldehyde phosphate buffer overnight and then dehydrated and paraffin-embedded. Six  $\mu\text{m}$  sections were stained with haematoxylin and eosin. Lung injury was quantified in a blinded manner by adoption of a modified pre-existing scoring system as described [38], including size of alveolar spaces, thickness of alveolar septas, alveolar fibrin deposition and neutrophil infiltration graded on a 0 (absent) to 4 (extensive) scale. In each tissue sample, 5 random areas were scored and median value was calculated. The histology score was the sum of all four parameters.

### *In vitro activation of neutrophils*

Blood was collected from healthy animals containing 1:10 acid citrate dextrose. Whole blood was incubated with M1 protein (1  $\mu\text{g}/\text{ml}$ ) with or without FTI-277 (1 or 10  $\mu\text{M}$ ) and vehicle at 37°C for 20 min. Cells were stained for flow cytometric analysis of Mac-1 expression on neutrophils (Gr-1<sup>+</sup>) as described above.

### *Quantitative RT-PCR*

Mice were challenged with M1 protein for 30 min and alveolar macrophages were isolated as previously described (41). Total RNA was then isolated from alveolar macrophages by use of RNeasy Mini Kit (Qiagen, West Sussex, UK) and treated with RNase-free DNase (DNase I; Amersham Pharmacia Biotech, Sollentuna, Sweden) to remove potential genomic DNA contaminants. RNA concentrations were determined by measuring the absorbance at 260 nm. Each cDNA was synthesized by reverse transcription from 10 µg of total RNA by use of StrataScript First-Strand Synthesis System and random hexamers primers (Stratagene, AH diagnostics, Stockholm, Sweden). Real-time PCR was performed using a Brilliant SYBRgreen QPCR master mix and MX 3000P detection system (Stratagene). The primers sequences of CXCL1, CXCL2 and  $\beta$ -actin were as follows: CXCL1 (f) 5'-GCT TCC TCG GGC ACT CCA GAC -3', CXCL1 (r) 5'-TTA GCC TTG CCT TTG TTC AGT AT -3'; CXCL2 (f) 5'-GCC AAT GAG CTG CGC TGT CAA TGC -3', CXCL2(r) 5'-CTT GGG GAC ACC TTT TAG CAT CTT -3';  $\beta$ -actin (f) 5'-ATG TTT GAG ACC TTC AAC ACC-3',  $\beta$ -actin (r) 5'-TCT CCA GGG AGG AAG AGG AT-3'. Standard PCR curves were generated for each PCR product to establish linearity of the RT-PCR reaction. PCR amplifications were performed in a total volume of 50 µl, containing 25 µl of SYBRgreen PCR 2 x master mix, 2 µl of 0.15 µM each primer, 0.75 µl of reference dye, and one 1 µl cDNA as a template adjusted up to 50 µl with water. PCR reactions were started with 10 min denaturing temperature of 95°C, followed by a total of 40 cycles (95°C for 30 s and 55°C for 1 min) and 1 min of elongation at 72°C. The relative differences in expression between groups were expressed by using cycling time values. Cycling time values for the specific target genes were first normalized with that of  $\beta$ -actin in the same sample, and then relative differences between groups were expressed as percentage of control.

*Chemotaxis assay*

Neutrophils isolated from bone marrow by use of Ficoll-Paque™ were preincubated with FTI-277 (10  $\mu$  M) for 30 min, and  $1.5 \times 10^6$  neutrophils were placed in the upper chamber of the transwell inserts (5  $\mu$ m pore size; Corning Costar, Corning, NY, USA). Inserts were placed in wells containing medium alone (control) or medium plus CXCL2 (100 ng/ml; R&D Systems). After 120 min, inserts were removed, and migrated neutrophils were 1:1 transferred into 0.5% hexadecyltrimethylammonium bromide. Chemotaxis was determined by as MPO activity as described above.

*Statistics*

Data are presented as mean values  $\pm$  standard errors of the means (SEM). Statistical evaluations were performed using Kruskal-Wallis one-way analysis of variance on ranks followed by multiple comparisons versus control group (Dunnett's method).  $P < 0.05$  was considered significant and  $n$  represents the number of animals.

## RESULTS

### *Pulmonary edema and damage*

Challenge with M1 protein induced clear-cut lung injury, indicated by the significant increase in lung edema formation (Fig. 1). Thus, lung wet:dry ratio increased in M1 protein-treated animals from  $4.6 \pm 0.1$  to  $5.3 \pm 0.1$  (Fig. 1). Administration of 25 mg/kg of the farnesyltransferase inhibitor FTI-277 reduced lung wet:dry ratio to  $4.7 \pm 0.0$  in mice challenged with M1 protein (Fig. 1). Thus, inhibition of farnesyltransferase signaling decreased M1 protein-provoked lung edema by 77%. Moreover, morphologic examination revealed normal lung microarchitecture in sham-operated mice (Fig. 2A), whereas M1 protein caused clear-cut destruction of the lung tissue structure characterized by interstitial edema, capillary congestion and neutrophil accumulation (Fig. 2B). It was observed that inhibition of farnesyltransferase activity reduced M1 protein-provoked changes of the microarchitecture and neutrophil accumulation in the lung (Fig. 2D). Quantification of the morphological changes revealed that M1 protein increased the lung injury score and that administration of the farnesyltransferase inhibitor significantly decreased the lung injury score in animals challenged with M1 protein (Fig. 2E).

### *Neutrophil infiltration*

Injection of M1 protein increased lung levels of MPO by more than 10-fold (Fig. 3A). Inhibition of farnesyltransferase signaling reduced the M1 protein-provoked increase in pulmonary MPO activity by 34% (Fig. 3A). Quantification of BALF neutrophils revealed a massive enhancement in the number of alveolar neutrophils 4 h after administration of M1 protein (Fig. 3B). We observed that treatment with 25 mg/kg of FTI-277 reduced number of pulmonary neutrophils from  $101.6 \pm 5.9 \times 10^3$  to  $46.4 \pm 5.5 \times 10^3$  in the lung, corresponding to a 73% reduction, 4 h

after M1 protein challenge (Fig. 3B). Moreover, it was found that administration of M1 protein reduced the number of PMNLs and MNLs in the blood (Table 1). Inhibition of farnesyltransferase signaling significantly reduced this M1 protein-provoked leucopenia (Table 1).

#### *CXC chemokines in the lung*

CXC chemokine levels were low in the lungs of control mice (Fig. 4). M1 protein administration markedly increased pulmonary levels of CXCL1 and CXCL2 by 233-fold and 30-fold respectively (Fig. 4). Treatment with FTI-277 abolished M1 protein-induced formation of CXCL1 and CXCL2 (Fig. 4). We next isolated alveolar macrophages in BALF with purity higher than 94% (Fig. 5A). Gene expression of CXC chemokines was examined in alveolar macrophages isolated from mice challenged with M1 protein and pretreated with FTI-277 or vehicle. We found that M1 protein caused a marked enhancement of mRNA levels of CXCL1 and CXCL2 in alveolar macrophages. Notably, inhibition of farnesyltransferase abolished M1 protein-evoked gene expression of CXCL1 and CXCL2 in alveolar macrophages (Fig. 5B and 5C).

#### *Neutrophil migration and Mac-1 expression*

It was observed that 100 ng/ml CXCL2 caused a clear-cut increase in neutrophil migration over a time period of 120 min (Fig. 6). Preincubation of neutrophils with FTI-277 completely inhibited CXCL2-induced neutrophil migration *in vitro* (Fig. 6). Challenge with M1 protein triggered a significant increase in Mac-1 expression on neutrophils *in vivo* and *in vitro* (Fig. 7). However, we observed that inhibition of farnesyltransferase had no significant effect on M1 protein-induced

expression of Mac-1 on neutrophils *in vitro* or *in vivo* (Fig. 7).

## DISCUSSION

Management of patients with severe infections and respiratory failure poses a major challenge to clinicians due to the limited therapeutic options. Infections with *Streptococcus pyogenes* of the M1 serotype can cause STSS and acute lung injury. The present study demonstrates that administration of the farnesyltransferase inhibitor FTI-277 protects against lung damage triggered by streptococcal M1 protein. The protective effect of FTI-277 was related to a substantial reduction in neutrophil infiltration in the lung. FTI-277 has been widely tested and demonstrated to possess high specificity for farnesyltransferase (19,33), although one can ever exclude the small possibility of off-target effects at some level. Nonetheless, our data indicate that inhibition of farnesyltransferase abolished CXC chemokine formation in lung macrophages in animals exposed to M1 protein. Our data suggest that farnesyltransferase is an important regulator of pulmonary recruitment of neutrophils and tissue damage in streptococcal infections.

Treatment of patients with STSS is largely restricted to supportive care due to an insufficient understanding of the underlying pathophysiology. Soluble M1 protein derived from the surface of *Streptococcus pyogenes* is a powerful stimulator of innate immunity causing activation of neutrophils, monocytes and platelets (14, 25, 26). We have recently reported that treatment with simvastatin inhibits streptococcal M1 protein-induced lung damage in mice although the mechanisms remain elusive (38). Statins not only reduce cholesterol levels but also formation of farnesyl pyrophosphate and geranylgeranyl pyrophosphate, constituting components in protein isoprenylation, such as farnesylation and geranylgeranylation (9, 11). Farnesylation regulates several protein functions, including membrane localization, activity and protein interactions. Accumulating studies have reported that inhibition of farnesyltransferase inhibits pro-inflammatory activities, such as inhibition of NF- $\kappa$ B and Ras activation (23, 28).

Herein, we show that inhibition of farnesyltransferase protects against M1 protein-provoked lung edema and tissue injury. These findings are in line with two previous reports showing that farnesyltransferase inhibition reduces apoptosis and mortality in endotoxemia and abdominal sepsis (31, 37). Knowing that neutrophil accumulation is considered to be a rate-limiting step in septic lung injury and that activation of circulating neutrophils is a prominent feature in M1 protein-induced lung damage (12, 40), it was of great interest to study pulmonary infiltration of neutrophils. In the present study, we could demonstrate that FTI-277 reduced M1 protein-induced lung activity of MPO, a marker of neutrophil recruitment, suggesting that farnesyltransferase is an important regulator of neutrophil trafficking in streptococcal infections. This reduction in MPO activity is also in line with the inhibition of neutrophil accumulation in the alveolar space in FTI-277 treated mice exposed to M1 protein. Indeed, this is the first study showing that inhibition of farnesyltransferase can inhibit tissue accumulation of neutrophils. These findings might also help to explain the decreased mortality in endotoxemic and septic mice treated with FTI-277 (31, 37). Nonetheless, keeping in mind the close relationship between neutrophil accumulation and lung damage, it may be forwarded that the lung protective effect of FTI-277 might be due to attenuation of neutrophil infiltration.

Leukocyte accumulation at sites of inflammation is a multistep process mediated by specific adhesion molecules. In the lung, several studies have shown that P-selectin glycoprotein ligand-1 (PSGL-1) as well as the  $\beta_2$ -integrins LFA-1 and Mac-1 on neutrophils mediate their extravascular accumulation in septic lung injury (1, 6). Notably, one report showed that the tetrapeptide Gly-Pro-Arg-Pro attenuates M1 protein-provoked lung injury, suggesting that  $\beta_2$ -integrins may be useful targets in severe streptococcal infections (14). Thus, we next asked whether farnesyltransferase inhibition might change neutrophil expression of Mac-1. As shown



before (40), we observed that systemic challenge with M1 protein increased Mac-1 on neutrophils. However, administration of FTI-277 had no effect on M1 protein-triggered expression of Mac-1 on neutrophils *in vivo* or *in vitro*, indicating that Mac-1 is not a protective target of FTI-277 in streptococcal infections. On one hand, we have recently observed that simvastatin had no significant impact on M1 protein-induced neutrophil expression of Mac-1 *in vitro* but on the other hand simvastatin was found to decrease Mac-1 expression on circulating neutrophils in mice exposed to M1 protein (38). These findings indicate that although simvastatin and FTI-277 exert overlapping anti-inflammatory effects, simvastatin also exerts farnesyltransferase-independent effects *in vivo* in M1 protein-induced inflammation. Whether such statin-mediated farnesyltransferase-independent effects might be regulated by geranylgeranylation-dependent signalling is not known and should be addressed in future studies. Extravascular navigation of neutrophils is orchestrated by secreted chemokines (7, 30). Neutrophils are particularly responsive to CXC chemokines, comprising CXCL1 and CXCL2, which are murine homologues of human interleukin-8 (42). Convincing evidence has demonstrated clear-cut formation of CXC chemokines in streptococcal infections (8, 15), and we have recently observed that M1 protein triggers significant pulmonary formation of CXCL1 and CXCL2 (40). Thus, we next asked whether farnesyltransferase might regulate M1 protein-induced formation of CXC chemokines in the lung. Indeed, we found that inhibition of farnesyltransferase greatly decreased M1 protein-evoked generation of CXCL1 and CXCL2 in the lung. Interestingly, similar reductions in M1 protein-induced pulmonary formation of CXC chemokines have been observed in mice treated with simvastatin (38). Moreover, we found that M1 protein markedly enhanced CXCL1 and CXCL2 mRNA levels in alveolar macrophages. Notably, administration of FTI-277 abolished M1 protein-provoked gene expression of CXC

chemokines in alveolar macrophages, indicating that farnesyltransferase activity is an important signalling pathway in macrophage production of CXC chemokines in streptococcal infections. Considering a previous study showing that CXC chemokines via their high-affinity receptor CXCR2 are critical in supporting M1 protein-induced accumulation of neutrophils in the lung (38), our current results suggest that inhibition of CXC chemokine generation helps to explain the regulatory role of farnesyltransferase in M1 protein-induced lung injury.

Our novel findings demonstrate that farnesyltransferase is an important regulator of neutrophil-mediated acute lung injury triggered by streptococcal M1 protein. Moreover, we demonstrate that inhibition of farnesyltransferase abolishes macrophage-dependent generation of CXC chemokines in response to M1 protein challenge. Thus, we conclude that these farnesyltransferase-dependent mechanisms may, at least in part, help to clarify the beneficial effects exerted by statins and that targeting farnesyltransferase activity might be useful in order to protect against respiratory failure in streptococcal infections.

AUTHORSHIP

Songen Zhang, Milladur Rahman and Su Zhang performed experiments and wrote the manuscript.

Bengt Jeppsson, Heiko Herwald and Henrik Thorlacius supervised the project, designed the experiments and wrote the manuscript.

#### ACKNOWLEDGMENTS

This work was supported by grants from the Swedish Medical Research Council (2009-4872), Einar och Inga Nilssons stiftelse, Mossfelts stiftelse, Allmänna sjukhusets i Malmö stiftelse för bekämpande av cancer, MAS fonder, Malmö University Hospital and Lund University.

#### DISCLOSURE

Authors have no financial disclosure.

## REFERENCES

1. Asaduzzaman, M., S. Zhang, S. Lavasani, Y. Wang, and H. Thorlacius. 2008. LFA-1 and MAC-1 mediate pulmonary recruitment of neutrophils and tissue damage in abdominal sepsis. *Shock* 30:254-259.
2. Baracco, G. J., and A. L. Bisno. 1999. Therapeutic Approaches to Streptococcal Toxic Shock Syndrome. *Curr Infect Dis Rep* 1:230-237.
3. Beltowski, J., G. Wojcicka, and A. Jamroz-Wisniewska. 2009. Adverse effects of statins - mechanisms and consequences. *Curr Drug Saf* 4:209-228.
4. Collin, M., and A. Olsen. 2000. Generation of a mature streptococcal cysteine proteinase is dependent on cell wall-anchored M1 protein. *Mol Microbiol* 36:1306-1318.
5. Cunningham, M. W. 2000. Pathogenesis of group A streptococcal infections. *Clin Microbiol Rev* 13:470-511.
6. Ding, Z. M., J. E. Babensee, S. I. Simon, H. Lu, J. L. Perrard, D. C. Bullard, X. Y. Dai, S. K. Bromley, M. L. Dustin, M. L. Entman, C. W. Smith, and C. M. Ballantyne. 1999. Relative contribution of LFA-1 and Mac-1 to neutrophil adhesion and migration. *J Immunol* 163:5029-5038.
7. Ebnet, K., and D. Vestweber. 1999. Molecular mechanisms that control leukocyte extravasation: the selectins and the chemokines. *Histochem Cell Biol* 112:1-23.
8. Fritzer, A., B. Noiges, D. Schweiger, A. Rek, A. J. Kungl, A. von Gabain, E. Nagy, and A. L. Meinke. 2009. Chemokine degradation by the Group A streptococcal serine proteinase ScpC can be reconstituted in vitro and requires two separate domains. *Biochem J* 422:533-542.
9. Gazzero, P., M. C. Proto, G. Gangemi, A. M. Malfitano, E. Ciaglia, S. Pisanti, A. Santoro, C. Laezza, and M. Bifulco. 2012. Pharmacological actions of statins: a critical appraisal in the management of cancer. *Pharmacol Rev* 64:102-146.
10. Giusti-Paiva, A., M. R. Martinez, J. V. Felix, M. J. da Rocha, E. C. Carnio, L. L. Elias, and J. Antunes-Rodrigues. 2004. Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. *Shock* 21:271-275.
11. Greenwood, J., L. Steinman, and S. S. Zamvil. 2006. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. *Nat Rev Immunol* 6:358-370.
12. Grommes, J., and O. Soehnlein. 2011. Contribution of neutrophils to acute lung injury. *Mol Med* 17:293-307.

13. Herbold, W., R. Maus, I. Hahn, N. Ding, M. Srivastava, J. W. Christman, M. Mack, J. Reutershan, D. E. Briles, J. C. Paton, C. Winter, T. Welte, and U. A. Maus. 2010. Importance of CXC chemokine receptor 2 in alveolar neutrophil and exudate macrophage recruitment in response to pneumococcal lung infection. *Infect Immun* 78:2620-2630.
14. Herwald, H., H. Cramer, M. Morgelin, W. Russell, U. Sollenberg, A. Norrby-Teglund, H. Flodgaard, L. Lindbom, and L. Bjorck. 2004. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. *Cell* 116:367-379.
15. Hidalgo-Grass, C., I. Mishalian, M. Dan-Goor, I. Belotserkovsky, Y. Eran, V. Nizet, A. Peled, and E. Hanski. 2006. A streptococcal protease that degrades CXC chemokines and impairs bacterial clearance from infected tissues. *EMBO J* 25:4628-4637.
16. Huber, A. R., S. L. Kunkel, R. F. Todd, 3rd, and S. J. Weiss. 1991. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. *Science* 254:99-102.
17. Kopterides, P., and M. E. Falagas. 2009. Statins for sepsis: a critical and updated review. *Clin Microbiol Infect* 15:325-334.
18. Lancet, J. E., and J. E. Karp. 2003. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. *Blood* 102:3880-3889.
19. Lerner, E. C., Y. Qian, M. A. Blaskovich, R. D. Fossum, A. Vogt, J. Sun, A. D. Cox, C. J. Der, A. D. Hamilton, and S. M. Sebti. 1995. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. *J Biol Chem* 270:26802-26806.
20. McGarry, M. P., and C. C. Stewart. 1991. Murine eosinophil granulocytes bind the murine macrophage-monocyte specific monoclonal antibody F4/80. *J Leukoc Biol* 50:471-478.
21. Merx, M. W., E. A. Liehn, J. Graf, A. van de Sandt, M. Schaltenbrand, J. Schrader, P. Hanrath, and C. Weber. 2005. Statin treatment after onset of sepsis in a murine model improves survival. *Circulation* 112:117-124.
22. Merx, M. W., E. A. Liehn, U. Janssens, R. Lutticken, J. Schrader, P. Hanrath, and C. Weber. 2004. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. *Circulation* 109:2560-2565.
23. Na, H. J., S. J. Lee, Y. C. Kang, Y. L. Cho, W. D. Nam, P. K. Kim, K. S. Ha, H. T. Chung, H. Lee, Y. G. Kwon, J. S. Koh, and Y. M. Kim. 2004. Inhibition of farnesyltransferase prevents collagen-induced arthritis by down-regulation of inflammatory gene expression through suppression of p21(ras)-dependent NF-kappaB activation. *J Immunol* 173:1276-1283.

24. Page, A. V., M. Kotb, A. McGeer, D. E. Low, K. C. Kain, and W. C. Liles. 2011. Systemic dysregulation of angiopoietin-1/2 in streptococcal toxic shock syndrome. *Clin Infect Dis* 52:e157-161.
25. Pahlman, L. I., M. Morgelin, J. Eckert, L. Johansson, W. Russell, K. Riesbeck, O. Soehnlein, L. Lindbom, A. Norrby-Teglund, R. R. Schumann, L. Bjorck, and H. Herwald. 2006. Streptococcal M protein: a multipotent and powerful inducer of inflammation. *J Immunol* 177:1221-1228.
26. Pahlman, L. I., A. I. Olin, J. Darenberg, M. Morgelin, M. Kotb, H. Herwald, and A. Norrby-Teglund. 2008. Soluble M1 protein of *Streptococcus pyogenes* triggers potent T cell activation. *Cell Microbiol* 10:404-414.
27. Rowinsky, E. K., J. J. Windle, and D. D. Von Hoff. 1999. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. *J Clin Oncol* 17:3631-3652.
28. Saha, B., and D. Nandi. 2009. Farnesyltransferase inhibitors reduce Ras activation and ameliorate acetaminophen-induced liver injury in mice. *Hepatology* 50:1547-1557.
29. Schmidt, H., R. Hennen, A. Keller, M. Russ, U. Muller-Werdan, K. Werdan, and M. Buerke. 2006. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. *Intensive Care Med* 32:1248-1251.
30. Schramm, R., and H. Thorlacius. 2003. Staphylococcal enterotoxin B-induced acute inflammation is inhibited by dexamethasone: important role of CXC chemokines KC and macrophage inflammatory protein 2. *Infect Immun* 71:2542-2547.
31. Shinozaki, S., Y. Inoue, W. Yang, M. Fukaya, E. A. Carter, Y. M. Yu, A. Fischman, R. Tompkins, and M. Kaneki. 2010. Farnesyltransferase inhibitor improved survival following endotoxin challenge in mice. *Biochem Biophys Res Commun* 391:1459-1464.
32. Soehnlein, O., S. Oehmcke, X. Ma, A. G. Rothfuchs, R. Frithiof, N. van Rooijen, M. Morgelin, H. Herwald, and L. Lindbom. 2008. Neutrophil degranulation mediates severe lung damage triggered by streptococcal M1 protein. *Eur Respir J* 32:405-412.
33. Sun, J., Y. Qian, A. D. Hamilton, and S. M. Sebti. 1995. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. *Cancer Res* 55:4243-4247.
34. Terblanche, M., Y. Almog, R. S. Rosenson, T. S. Smith, and D. G. Hackam. 2007. Statins and sepsis: multiple modifications at multiple levels. *Lancet Infect Dis* 7:358-368.
35. Walters, C. E., G. Pryce, D. J. Hankey, S. M. Sebti, A. D. Hamilton, D. Baker, J. Greenwood, and P. Adamson. 2002. Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system

- and attenuates clinical signs of disease in an animal model of multiple sclerosis. *J Immunol* 168:4087-4094.
36. Weber, C., W. Erl, K. S. Weber, and P. C. Weber. 1997. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. *J Am Coll Cardiol* 30:1212-1217.
  37. Yang, W., M. Yamada, Y. Tamura, K. Chang, J. Mao, L. Zou, Y. Feng, K. Kida, M. Scherrer-Crosbie, W. Chao, F. Ichinose, Y. M. Yu, A. J. Fischman, R. G. Tompkins, S. Yao, and M. Kaneki. 2011. Farnesyltransferase inhibitor FTI-277 reduces mortality of septic mice along with improved bacterial clearance. *J Pharmacol Exp Ther* 339:832-841.
  38. Zhang, S., M. Rahman, Z. Qi, H. Herwald, and H. Thorlacius. 2011. Simvastatin regulates CXC chemokine formation in streptococcal M1 protein-induced neutrophil infiltration in the lung. *Am J Physiol Lung Cell Mol Physiol* 300:L930-939.
  39. Zhang, S., M. Rahman, Z. Qi, and H. Thorlacius. 2011. Simvastatin antagonizes CD40L secretion, CXC chemokine formation, and pulmonary infiltration of neutrophils in abdominal sepsis. *J Leukoc Biol* 89:735-742.
  40. Zhang, S., S. Zhang, M. Rahman, H. Herwald, and H. Thorlacius. 2011. Streptococcal M1 protein-induced lung injury is independent of platelets in mice. *Shock* 35:86-91.
  41. Zhang, X., R. Goncalves, and D. M. Mosser. 2008. The isolation and characterization of murine macrophages. *Curr Protoc Immunol* Chapter 14:Unit 14 11.
  42. Zhang, X. W., Q. Liu, Y. Wang, and H. Thorlacius. 2001. CXC chemokines, MIP-2 and KC, induce P-selectin-dependent neutrophil rolling and extravascular migration in vivo. *Br J Pharmacol* 133:413-421.

## FIGURE LEGENDS

Figure 1. Edema formation in the lung. Mice were treated with the farnesyltransferase inhibitor FTI-277 (2.5 or 25 mg/kg) or vehicle (PBS) 10 min prior to M1 protein injection. Mice treated with PBS served as sham animals. Data represents mean  $\pm$  SEM, \* $P < 0.05$  vs. Sham and # $P < 0.05$  vs. Vehicle + M1 protein,  $n = 5$ .

Figure 2. Representative haematoxylin & eosin sections of lung. (A) Sham animals were treated with PBS only. Separate mice were pretreated with (B) vehicle (PBS) and (C) 2.5 or (D) 25 mg/kg FTI-277 10 min prior to M1 protein administration. Samples were harvested 4 h after M1 protein challenge. Scale bar indicates 100  $\mu$  m. (E) Histology score of lung injury. Data represents mean  $\pm$  SEM, \* $P < 0.05$  vs. Sham and # $P < 0.05$  vs. Vehicle + M1 protein,  $n = 5$ .

Figure 3. Farnesyltransferase regulates M1 protein-induced pulmonary infiltration of neutrophils. (A) MPO levels and (B) number of BALF neutrophils in the lung. Animals were treated with FTI-277 (2.5 or 25 mg/kg) or vehicle (PBS) 10 min prior to M1 protein injection. Samples were harvested 4 h after M1 protein challenge. Mice treated with PBS served as sham animals. Data represents mean  $\pm$  SEM, \* $P < 0.05$  vs. Sham and # $P < 0.05$  vs. Vehicle + M1 protein,  $n = 5$ .

Figure 4. Farnesyltransferase regulates CXC chemokine formation in the lung. Animals were treated with FTI-277 (2.5 or 25 mg/kg) or vehicle (PBS) 10 min prior to M1 protein injection. Mice treated with PBS served as sham animals. ELISA was used to quantify the levels of (A) CXCL1 and (B) CXCL2 in the lung of mice 4 h after M1 protein challenge. Data represents mean  $\pm$  SEM, \* $P < 0.05$  vs. Sham and # $P < 0.05$  vs. Vehicle + M1 protein,  $n = 5$ .



Figure 5. Farnesyltransferase regulates gene expression of CXC chemokines in alveolar macrophages. (A) F4/80 expression on isolated macrophages from BALF. Quantitative RT-PCR was used to determine mRNA levels of (B) CXCL1 and (C) CXCL2 in alveolar macrophages 30 min after M1 protein injection. Levels of CXCL1 and CXCL2 mRNA were normalized to mRNA levels of  $\beta$ -actin. Data represents mean  $\pm$  SEM, \* $P$  < 0.05 vs. Sham and # $P$  < 0.05 vs. Vehicle + M1 protein,  $n = 5$ .

Figure 6. Farnesyltransferase inhibits neutrophil migration *in vitro*. Neutrophil migration was determined in response to medium alone (Control), medium plus CXCL2 (100 ng/ml), with or without preincubation of neutrophils with FTI-277 (10  $\mu$  M). Data represents mean  $\pm$  SEM, \* $P$  < 0.05 vs. Control and # $P$  < 0.05 vs. CXCL2,  $n = 5$ .

Figure 7. Farnesyltransferase does not regulate M1 protein-induced Mac-1 expression on neutrophils. (A) and (C) show Mac-1 expression on neutrophils in vehicle (PBS) or FTI-277 (2.5 or 25 mg/kg) treated animals 4 h after M1 protein injection. (B) and (D) show Mac-1 expression on neutrophils *in vitro*. Whole blood was incubated with PBS only, or M1 protein (1  $\mu$ g/ml) and vehicle (PBS) or FTI-277 (10  $\mu$  M). Samples were harvested 4 h after M1 protein challenge. Fluorescence intensity of Mac-1 is shown on the x-axis and cell counts on the y-axis. Data represents mean  $\pm$  SEM, \* $P$  < 0.05 vs. Sham,  $n = 5$ .

Table 1. Systemic leukocyte differential counts

	MNL	PMNL	Total
Sham	4.0 ± 0.2	1.3 ± 0.1	5.2 ± 0.3
Vehicle + M1 Protein	0.8 ± 0.1*	0.3 ± 0.0*	1.1 ± 0.1*
FTI-277 (2.5) + M1 Protein	3.9 ± 0.5 <sup>#</sup>	1.0 ± 0.2 <sup>#</sup>	5.0 ± 0.5 <sup>#</sup>
FTI-277 (25) + M1 Protein	3.4 ± 0.5 <sup>#</sup>	1.2 ± 0.2 <sup>#</sup>	4.6 ± 0.6 <sup>#</sup>

Blood was collected from sham animals receiving PBS i.v. only as well as mice treated with FTI-277 (2.5 or 25 mg/kg) or vehicle before challenge with M1 protein for 4 h. Cells were identified as monomorphonuclear leukocytes (MNLs) and polymorphonuclear leukocytes (PMNLs). Data represents mean ± SEM, 10<sup>6</sup> cells/ml and  $n = 5$ , □  $P < 0.05$  vs. Sham and <sup>#</sup> $P < 0.05$  vs. Vehicle + M1 protein,  $n = 5$ .






Figure 1

A)




Sham

B)




Vehicle + M1 Protein

C)



FTI-277 2.5 + M1 Protein

D)



FTI-277 25 + M1 Protein

□ Sham  
■ M1 Protein

E)





Figure 2

A)



B)





Figure 3

A)



B)






Figure 4

A)



F4/80 expression on macrophages in BALF

B)



C)




Figure 5




Figure 6







Figure 7